LONDON (Alliance News) - Hutchison China MediTech Ltd said Wednesday its majority owned research and development company has begun the first in-human Phase I clinical trial of HMPL-523 for autoimmune diseases. Hutchinson MediPharma Ltd has begun the trial in Australia, with the aim of estab Read More

Hutchinson China MediTech Launches Phase II Lung Cancer Drug Trial

5th Jun 2014 11:22

LONDON (Alliance News) - Hutchinson China MediTech Ltd said Thursday that its majority owned research and development company has begun a Phase II clinical trial of drug fruquintinib for the treatment of non-small cell lung cancer in China. The trial is targeted at patients who have failed Read More

DIRECTOR DEALINGS: Hutchinson China MediTech Non-Executive Buys Shares

4th Jun 2014 13:39

LONDON (Alliance News) - Hutchinson China MediTech Ltd said Wednesday that Independent Non-Executive Director Christopher Nash bought 4,036 shares at 842 pence each. Following this transaction, Nash's interest in the China-based healthcare company is 0.06%. Shares in China MediTech we Read More

Hutchison China MediTech's JV Gets Rights To Six Drugs From Partner

30th May 2014 08:37

LONDON (Alliance News) - Hutchison China MediTech Ltd Friday said Shanghai Traditional Chinese Medicine Co. Ltd has decided to grant the two companies' joint venture exclusive rights to sell six prescription drug products in China. In a statement, Chi-Med said the Shanghai Hutchison Pharmac Read More

5 6 7 8 9 10 11 121314

FTSE 100 Latest

Value8,809.74

Change53.53